• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

Comprehensive Overview of tert-butyl 7-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate (CAS No. 2411641-36-4)

The compound tert-butyl 7-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate (CAS No. 2411641-36-4) is a bicyclic organic molecule featuring a unique 3-azabicyclo[4.1.0]heptane core structure. This scaffold is of significant interest in medicinal chemistry due to its potential applications in drug discovery, particularly in the design of protease inhibitors and modulators of central nervous system (CNS) targets. The presence of both a hydroxymethyl group and a tert-butyl carboxylate moiety enhances its versatility as a synthetic intermediate.

Recent trends in pharmaceutical research highlight the growing demand for bicyclic heterocycles like 3-azabicyclo[4.1.0]heptane derivatives. These structures are frequently explored for their conformational rigidity, which can improve binding affinity and metabolic stability in drug candidates. Researchers often search for "synthesis of azabicyclo compounds" or "applications of tert-butyl carboxylates in drug design," reflecting the compound's relevance in modern organic synthesis.

The hydroxymethyl functional group in tert-butyl 7-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate offers a handle for further derivatization, enabling the introduction of pharmacophores or linking to other molecular fragments. This property aligns with the current focus on "click chemistry in drug discovery" and "fragment-based lead optimization," topics frequently queried in academic and industrial settings.

From a synthetic perspective, the tert-butyl ester group serves as a protecting strategy for carboxylic acids, a technique widely discussed in forums on "protecting group strategies in organic synthesis." The stability of the tert-butyl moiety under basic conditions makes this compound particularly useful for multi-step reactions, a feature highly valued in complex molecule assembly.

Analytical characterization of CAS No. 2411641-36-4 typically involves advanced techniques such as NMR spectroscopy, mass spectrometry, and X-ray crystallography. These methods are essential for confirming the stereochemistry of the azabicyclo[4.1.0]heptane system, a critical quality attribute given the increasing regulatory emphasis on "chiral purity in pharmaceutical intermediates."

In the context of green chemistry initiatives, the development of efficient catalytic methods to access 3-azabicyclo[4.1.0]heptane derivatives has become a hot topic. Search queries like "sustainable synthesis of nitrogen heterocycles" reflect this trend, positioning tert-butyl 7-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate as a compound of interest for environmentally conscious synthetic routes.

The pharmaceutical industry's shift toward targeted therapies has increased scrutiny of molecular properties such as ligand efficiency metrics and three-dimensional molecular complexity. The compact, yet functionalized structure of CAS No. 2411641-36-4 makes it a valuable template for addressing these contemporary challenges in lead compound development.

Recent patent literature reveals growing intellectual property activity around azabicycloheptane derivatives, particularly in areas of kinase inhibition and GPCR modulation. This commercial interest underscores the importance of tert-butyl 7-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate as a strategic building block in proprietary drug discovery programs.

From a regulatory standpoint, compounds like 2411641-36-4 benefit from being non-controlled substances, facilitating their use in international research collaborations. This characteristic responds to frequent searches about "non-restricted chemical intermediates for global research" in pharmaceutical development communities.

Future research directions for this compound class may explore its potential in emerging fields such as deuterium-labeled pharmaceuticals or PROTAC-based therapeutics, both areas generating substantial interest in medicinal chemistry circles. The structural features of tert-butyl 7-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate provide multiple sites for such innovative modifications.

• 1192688-51-9(Tert-Butyl 1-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate)
• 827599-21-3(endo-3-boc-3-azabicyclo[3.1.0]hexane-6-methanol)
• 419572-18-2(tert-butyl rel-(1R,5S,6r)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate)
• 2411641-73-9(tert-butyl 8-(hydroxymethyl)-5-azaspiro[2.5]octane-5-carboxylate)
• 1932212-13-9(6-Azaspiro[2.5]octane-6-carboxylic acid, 1-(hydroxymethyl)-, 1,1-dimethylethyl ester, (1S)-)
• 2229372-69-2(tert-butyl 3-{1-(hydroxymethyl)cyclopropylmethyl}piperidine-1-carboxylate)
• 2154256-66-1(tert-butyl 7-(1-hydroxyethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate)
• 203663-27-8(tert-butyl 6-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate)
• 2228612-34-6(tert-butyl 4-1-(hydroxymethyl)cyclopropyl-3-methylpiperidine-1-carboxylate)
• 850808-43-4(Tert-butyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate)